ReNeuron Group plc (LON:RENE – Get Free Report) was down 2.2% on Thursday . The stock traded as low as GBX 3.28 ($0.04) and last traded at GBX 3.38 ($0.04). Approximately 177,373 shares traded hands during trading, a decline of 69% from the average daily volume of 578,249 shares. The stock had previously closed at GBX 3.45 ($0.04).
ReNeuron Group Trading Down 2.2 %
The stock has a market capitalization of £1.93 million, a PE ratio of -37.50 and a beta of 0.83. The company has a current ratio of 1.51, a quick ratio of 2.02 and a debt-to-equity ratio of 14.25. The stock has a 50 day moving average price of GBX 3.38 and a 200-day moving average price of GBX 3.38.
ReNeuron Group Company Profile
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease.
Read More
- Five stocks we like better than ReNeuron Group
- Transportation Stocks Investing
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- 3 Healthcare Dividend Stocks to Buy
- Texas Instruments: The Old-School Tech Titan Still Delivering
- The Basics of Support and Resistance
- GRAIL: Biotech Stock Targeting $100B Cancer Market
Receive News & Ratings for ReNeuron Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReNeuron Group and related companies with MarketBeat.com's FREE daily email newsletter.
